MOMO'S BREAKOUT BOARD

[~BC~]

<<<<- CPBM DD Summary ->>>>


Contact Info:

Mr. Garth Likes
President/CEO
[e-mail]

Cyplasin Biomedical
Advanced Technology Center, 9650-20th Avenue,
Suite 131,
Edmonton, Alberta, [phone]

Company Website:

http://www.c-pharma.net/

Share Structure:

20M O/S Per Jan 13 News: http://www.newswire.ca/en/releases/archive/January2011/13/c2262.html
5M Float - Per CEO Email on 01/18/11: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58905651
5M Held by CEO: http://finance.yahoo.com/q/ir?s=CPBM.OB+Insider+Roster

Transfer Agent:

Pacific Stock Transfer Co.
4045 South Spencer St., Suite 403
Las Vegas, NV, 89119
702-361-3033
http://www.pacificstocktransfer.com
[e-mail]


Fully Reporting OTC:BB:
http://sec.gov/cgi-bin/browse-edgar?company=Cyplasin&match=&CIK=&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

The Company is now preparing to commercialize the following products:

* C-Virin – is a convenient, once-a-day oral formulation of ribavirin USP .Hepatitus C treatment

* C-Pegferon –is our brand of long-lasting, pegylated-interferon-alpha-2b. This product and C-Virin will be used
together for the treatment of genotype 1, 2, 3, and 4 strains of hepatitis C virus.

* C-Vaxin – is a bivalent VLP vaccine and adjuvant combination designed to be used for the prevention of genotype-1
HCV infections or as an active-specific immunotherapy of chronic HCV disease .Hepatitus C treatment

* C-Immune – is a genotype-1-specific human immune globulin (antibody) product made by donor plasma fractionation,
used for passive immunotherapy of HCV patients who fail to respond to ribavirin and interferon, and will be developed for
the prevention or delay of graft re-infection by HCV in liver transplant recipients whose livers have failed due to
chronic HCV infection.

Key Points From Recent News:

-Obtaining a third party valuation of $122 million for the Company as a component of an overall
corporate financing.

-The securing of a worldwide, exclusive license for a platform vaccine technology from the National Institutes of
Health which has applications initially for Hepatitis C ; but also has use in other applications such as cancer,
nervous system disorders and obesity. The licensed platform technology has had approximately $10 million invested in it
prior to the Company securing the license.

-Entering into a Letter of Agreement with Minapharm Pharma for potential co-product development and distribution
of Cyplasin's products within their territory.
NOTE: Minapharm is Huge: http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=MIPH:EY

-Negotiating final terms with a formulation specialty company to make a C- Virin product line.
Mr. Likes went on to say "the Company is aware of the continued downward pressure on the share price. However while
the capitalization number does not currently reflect our value; with the third party valuation number currently being at
$122 million and with there being approximately just under 20 million shares being issued, plus the
other technologies which can be developed from our technology license, we believe we will demonstrate during the
near, mid and long term execution of our business plan, that we bring value to our shareholders. We believe the market
will reward us accordingly".

Misc DD Posts:

Email From CEO (1/18):

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58905651

CPBM Patent Info:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58903646

CPBM Key Developments:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58903460

CPBM Cyplasin Biomedical Ltd Announces Supplier Aurobindo:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58840238

CPBM News on MinaPharm Website:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58852709

http://investorshub.advfn.com/boards/replies.aspx?msg=58852709

CPBM OTC Stock Review Profile:

http://www.stockvest.com/cpbm1.pdf

CPBM In BIOZINE Magazine (Page 4):

http://inkslingermedia.com/wp-content/uploads/2009/01/biozine-abridged.pdf

CPBM In Canada's HealthEdition Newsweekly Publication (Page 5):

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58912710


For more DD info, visit the CPBM board and view the iBox:

http://investorshub.advfn.com/boards/Board.aspx?board_id=14494


Charts: